Physical activity uptake in patients with HIV: who does how much?
Fillipas S, Bowtell-Harris CA, Oldmeadow LB, Cicuttini F, Holland AE, Cherry CL
Phase 1 single dose studies to optimize the pharmacokinetics of DG17, a novel HIV-protease inhibitor pro-drug, using sodium bicarbonate and ritonavir.
Cherry CL, Hoy JF, Rowe JS, Krum H, Mills J, Lewin SR
Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region.
Wright E, Brew B, Arayawichanont A, Robertson K, Samintharapanya K, Kongsaengdao S, Lim M, Vonthanak S, Lal L, Sarim C, Huffam S, Li P, Imran D, Lewis J, Lun WH, Kamarulzaman A, Tau G, Ali ST, Kishore K, Bain MP, Dwyer R, McCormack G, Hellard M, Cherry C, McArthur J, Wesselingh S
Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk.
Cherry CL, Rosenow A, Affandi JS, McArthur JC, Wesselingh SL, Price P
Replication-dependent pathogenicity of attenuated nef-deleted HIV-1 in vivo.
Gorry PR, Churchill M, Learmont J, Cherry C, Dyer WB, Wesselingh SL, Sullivan JS
Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006.
Smyth K, Affandi JS, McArthur JC, Bowtell-Harris C, Mijch AM, Watson K, Costello K, Woolley IJ, Price P, Wesselingh SL, Cherry CL